In all areas of our work, ITF Therapeutics is guided by the voices of the communities we serve. We value the special role that personal stories and experiences play in helping us understand the impact that rare diseases can have on families and caregivers. The voice of the community also helps us understand the most effective ways to partner with individuals living with rare diseases, their families, and healthcare professionals. It is an honor for us to collaborate with leaders in advocacy, research, and patient care as we work to build a brighter future for people living with rare diseases.
ITF Therapeutics is the US affiliate of Italfarmaco Group, a private global pharmaceutical company that was founded in 1938 in Milan, Italy. Our parent company has led the successful development of many innovative therapeutic products approved for use by patients around the world.
Italfarmaco operates in more than 90 countries on five continents and continues to advance promising research to address unmet medical needs in a wide range of therapeutic areas.
In January 2024, Italfarmaco launched ITF Therapeutics as a new division in the United States with a focus on the development and commercialization of products to treat rare diseases.
ITF Therapeutics partners with leaders from the US patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics reflects Italfarmaco’s goal to build a world-class team of experts who share a passion to make a positive impact for rare disease communities.
Working in close collaboration with patient advocates and clinical leaders, our goal is to help make a positive difference for people living with many different rare diseases.
Matt Trudeau, President, ITF Therapeutics
